Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia

Main Article Content

A. D’Alessio
M. Cottini
C. Lombardi
M. Uccelli
F. Bracchi
G. Cesana
D. Di Mauro
A. Fargnoli
C. Giussani
F. Martini
M. Motta
S. Olmi
N. Sertori
M. Taverna
P. Del Poggio

Abstract

Background: Hydroxychloroquine (HCQ) has been used against SARS-CoV-2, but large non randomized studies failed to show any clinical benefit. However, in these studies the drug was started in the hospital setting, a significant time after the onset of symptoms.

Aim of the Study: to verify if HCQ, given early after the onset of symptoms and in the outpatient setting, can reduce hospital admissions and improve clinical outcomes of COVID-19

Methods: We performed a retrospective study on 824 patients with COVID-19 pneumonia in the Bergamo province (Lombardy, Italy). Patients were divided in 2 cohorts: the first included 354 outpatients attended by Primary Care Physicians (PCP), the second included 470 patients admitted to an Emergency Department (ED) during the same period. We compared rate of hospital admission and clinical outcomes in patients treated with HCQ within 6 days from the onset of symptoms, with all other patients. Clinical outcomes were evaluated at a 1-month time-point.

Results: Patients who received early treatment with HCQ showed a lower rate of hospital admissions (p<0.0001), mechanical ventilation (p<0.0022) and need for oxygen supplementation at home (p=0.002) in the first cohort and improved survival in the second (p=0.03). Early treatment with HCQ was the only independent variable influencing all predefined outcomes on multivariate analysis.

Conclusions: Treatment with HCQ, initiated within 6 days from the onset of COVID-19 may improve both clinical outcome and rate of hospital admissions.

Keywords:
SARS-CoV-2, COVID-19, hydroxychloroquine

Article Details

How to Cite
D’Alessio, A., Cottini, M., Lombardi, C., Uccelli, M., Bracchi, F., Cesana, G., Mauro, D. D., Fargnoli, A., Giussani, C., Martini, F., Motta, M., Olmi, S., Sertori, N., Taverna, M., & Poggio, P. D. (2021). Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia. Asian Journal of Medicine and Health, 19(2), 15-26. https://doi.org/10.9734/ajmah/2021/v19i230301
Section
Original Research Article

References

Johns Hopkins Univeristy of Medicine, Coronavirus Research Center. Available:https://coronavirus.jhu.edu/map.html

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-3. DOI:10.5582/bst.2020.01047

Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro. Cell Res. 2020;30:269-71. DOI:10.1038/s41422-020-0282-0

Yao X, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ClinInfect Dis; 2020. DOI:10.1093/cid/ciaa237

Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–704.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. NE Eng J Med April 10; 2020. DOI: 10.1056/NEJMoa2007016

Beigel J, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID.19 – preliminary report New Eng J Med. 2020;383:1-12. DOI: 10.1056/NEJMoa 2007764

Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet; 2020. Available:https://doi.org/10.1016/S0140-6736(20)31022-9

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery; 2020. DOI: 10.1038/s41421-020-0156-0.15

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends. 2020;14:72. DOI: 10.5582/bst.2020.01047

Gautret P, LagierJG, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents; 2020. DOI: 10.1016/j.ijantimicag.2020.105949

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis; 2020. Available:https://doi.org/10.1093/cid/ciaa237

Gautret P, Lagier JG, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: An observational study. Travel Medicine and Infectious Disease; 2020. DOI: 10.1016/ j.tmaid.2020.101663

Rosenberg ES, Dufort EM, Tomoko U ,Wilberschied LA, Tesoriero J, Weinberg P, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State JAMA; 2020. DOI:10.1001/jama.2020.8630

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of hydroxychloroquine in hospitalized patients with COVID-19 N Engl J Med. 2020;383:1-8. DOI: 10.1056/NEJMoa2012410

Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:1844. Available:http://dx.doi.org/10.1136/bmj.m1844

Million M, Gautret P, Colson P, Roussel Y, Dubourg G, Chabriere E, et al. Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between the Big data and the real world, New Microbes and New Infections; 2020. Available:https://doi.org/10.1016/j.nmni.2020.100709.

Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Medicine and Infectious Disease; 2020. DOI: https://doi.org/10.1016/j.tmaid.2020.101791

Levasseur A, Mailhe M, Ravaux I, Richez M, Roussel Y, Seng P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Medicine and Infectious Disease; 2020. DOI: https://doi.org/10.1016/j.tmaid.2020.101791

Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Factors for mortality in patients with COVID-19 in New York City. J Gen Intern Med Ahead of print; 2020. DOI: 10.1007/s11606-020-05983-z

Arshad A, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis Ahead of print; 2020. Available:https://doi.org/10.1016/j.ijid.2020.06.099

Lipworth B, Chan R, Lipworth S, Kuo C. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J Allergy Clin Immunol Pract. Ahead of Print; 2020. Available:https://doi.org/10.1016/j.jaip.2020.04.014

S I M I T. Società Italiana di malattie infettive e tropicali sezione regione lombardia. Linee guida sulla gestione terapeutica e di supporto per pazienti con infezione da coronavirus COVID-19 Available:https://www.omceoch.it/storage/attachments/Ebka.COVID19%20linee%20guida%20trattamento%2001MAR.pdf.pdf

Fagiuoli S, Lorini FL, Remuzzi G, Adaptations and lessons in the province of Bergamo. N Engl J Med. 2020;382:71. DOI: 10.1056/NEJMc2011599

Fiolet T, Guihur A, Rebeaud MA, Mulot M, Smadja NP, Saleh YM. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. Clin Microbiol Infect. 2021;27: 19-27.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease, 2019 (COVID-19): A review. JAMA; 2020. DOI: 10.1001/jama.2020.6019. Online ahead of print

Synowiec A, Szcepanski A, Barreto-Duran E, Lie LK, Pyrc K. Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2): A systemic infection. Clin Microbiol Rev. 2021;34:1-31. DOI:10.1128/CMR.00133-20

White N, Watson JA, Hoglund RM, Chan XH, Cheah PY, Tarning J. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Med. 2020;17(9):1-24. Available:https://doi.org/10.1371/journal.pmed.1003252

Onder G, Rezza G, Brusaferro S. Case fatality rate and characteristics of patients dying in relation to COVID.19 in Italy. JAMA; 2020. DOI: 10.1001/jama.2020.4683. Online ahead of print. PMID: 32203977

Tao Ai, Yang Z, Hou H, Zhan C, Chen C, Li W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases radiology. Online ahead of print. Radiology. 2020;200642. DOI: 10.1148/radiol.2020200642.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 2020;20(4): 425-434.

Guérin V, Lévy P, Thomas JL, Lardenois T, Lacrosse P, Sarrazin E, et al. Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate COVID-19 AJMAH. 2020;18(7):45-55.